Foundation Medicine Announces Presentations at ASCO

May 18, 2016

Foundation Medicine Announces Presentations at ASCO

--Data Supports Comprehensive Genomic Profiling for Identifying Therapeutic Treatment Options and Determining Predictors of Therapeutic Response Across Broad Cancer Types--

CAMBRIDGE, Mass. & CHICAGO--(BUSINESS WIRE)-- Foundation Medicine, Inc. (NASDAQ:FMI) today announced that the company and its collaborators will have two oral presentations, six poster discussions and nineteen posters presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2016 taking place June 3-7 in Chicago.

The schedule for oral presentations by Foundation Medicine and/or its collaborators is as follows:

Date and Time: Sunday, June 5, 2015 from 9:57 - 10:09 a.m. CT
Title: PD-L1 Expression, Cancer Genome Atlas (TCGA) Subtype and Mutational Load are Independent Predictors of Response to Atezolizumab (atezo) in Metastatic Urothelial Carcinoma (mUC; IMvigor210)
Abstract Number: 104
Location: Hall D1
Session: Immunotherapy: Now We're Getting Personal - Using Genomics and Biomarkers to Predict Response
Session Type: Clinical Science Symposium
Presenter: Jonathan E. Rosenberg, M.D., medical oncologist, Memorial Sloan Kettering Cancer Center
Collaborator(s): Memorial Sloan Kettering Cancer Center

Date and Time: Sunday, June 5, 2016 from 10:21 - 10:33 a.m. CT
Title: Hybrid Capture-Based Next-Generation Sequencing (HC NGS) in Melanoma to Identify Markers of Response to Anti-PD-1/PD-L1
Abstract Number: 105
Location: Hall D1
Session: Immunotherapy: Now We're Getting Personal - Using Genomics and Biomarkers to Predict Response
Session Type: Clinical Science Symposium
Presenter: Douglas Buckner Johnson, M.D., M.S.C.I., clinical director, melanoma, Vanderbilt-Ingram Cancer Center
Collaborator(s): Vanderbilt University

The schedule for poster discussions by Foundation Medicine and/or its collaborators is as follows:

Date and Time: Saturday, June 4, 2016 from 8:00 - 11:30 a.m. CT
Discussion Time: 3:00 - 4:15 p.m. CT
Title: Genomic Profiling to Distinguish Poorly Differentiated Neuroendocrine Carcinomas Arising in Different Sites
Abstract Number: 4020
Poster Board Number: 12
Poster Display Location: Hall A
Discussion Location: Hall D1
Session: Gastrointestinal (Noncolorectal) Cancer
Presenter: Emily K. Bergsland, M.D., endowed chair in medical oncology, University of California San Francisco
Collaborator(s): University of California San Francisco, Helen Diller Family Comprehensive Cancer Center

Date and Time: Saturday, June 4, 2016 from 8:00 - 11:30 a.m. CT
Discussion Time: 3:00 - 4:15 p.m. CT
Title: Total Mutation Burden (TMB) in Lung Cancer (LC) and Relationship with Response to PD-1/PD-L1 Targeted Therapies
Abstract Number: 9017
Poster Board Number: 340
Poster Display Location: Hall A
Discussion Location: E354b
Session: Lung Cancer - Non-Small Cell Metastatic
Presenter: David R. Spigel, M.D., chief scientific officer; director, lung cancer research program; principal investigator, Sarah Cannon Research Institute
Collaborator(s): Sarah Cannon Research Institute

Date and Time: Saturday, June 4, 2016 from 8:00 - 11:30 a.m. CT
Discussion Time: 3:00 - 4:15 p.m. CT
Title: Comprehensive Genomic Profiling of 298 Lung Cancers of Varying Histologies Harboring MET Exon 14 Alterations
Abstract Number: 9021
Poster Board Number: 344
Poster Display Location: Hall A
Discussion Location: E354b
Session: Lung Cancer - Non-Small Cell Metastatic
Presenter: Sai-Hong Ignatius Ou, M.D., Ph.D., medical oncologist, Chao Family Comprehensive Cancer Center, University of California Irvine
Collaborator(s): Chao Family Comprehensive Cancer Center, University of California Irvine

Date and Time: Saturday, June 4, 2016 from 1:00 - 4:30 p.m. CT
Discussion Time: 4:45 - 6:00 p.m. CT
Title: Comprehensive Genomic Sequencing (CGS) of 90 Patient Samples of Anaplastic Thyroid Cancer (ATC)
Abstract Number: 6014
Poster Board Number: 336
Poster Display Location: Hall A
Discussion Location: S406
Session: Head and Neck Cancer
Presenter: Saad A. Khan, M.D., medical oncologist, The University of Texas Southwestern Medical Center
Collaborator(s): The University of Texas Southwestern Medical Center

Date and Time: Monday, June 6, 2016 from 8:00 - 11:30 a.m. CT
Discussion Time: 1:15 - 2:30 p.m. CT
Title: Evaluation of Microsatellite Instability (MSI) Status in 11,573 Diverse Solid Tumors using Comprehensive Genomic Profiling (CGP)
Abstract Number: 1523
Poster Board Number: 346
Poster Display Location: Hall A
Discussion Location: S404
Session: Cancer Prevention, Hereditary Genetics and Epidemiology
Presenter: Michael J. Hall, M.D., M.S., associate professor; director, gastrointestinal risk assessment, Fox Chase Cancer Center
Collaborator(s): Fox Chase Cancer Center

Date and Time: Monday, June 6, 2016 from 1:00 - 4:30 p.m. CT
Discussion Time: 4:45 - 6:00 p.m. CT
Title: DNA-Based Genomic Profiling for Classification of Tissue of Origin for Patients with Carcinoma of Unknown Primary Site
Abstract Number: 11519
Poster Board Number: 216
Poster Display Location: Hall A
Discussion Location: S406
Session: Tumor Biology
Presenter: Michael Goldberg, clinical data analyst II cancer genomics, Foundation Medicine

The schedule for poster presentations by Foundation Medicine and/or its collaborators is as follows:

Date and Time: Saturday, June 4, 2016 from 8:00 - 11:30 a.m. CT
Title: Tumor Mutational Burden as a Potential Biomarker for PD-11/PD-L1 Therapy in Colorectal Cancer
Abstract Number: 3587
Poster Board Number: 284
Poster Display Location: Hall A
Session: Gastrointestinal (Colorectal) Cancers
Presenter: Thomas J. George, M.D., F.A.C.P., medical director, gastrointestinal oncology, University of Florida
Collaborator(s): University of Florida

Date and Time: Saturday, June 4, 2016 from 8:00 - 11:30 a.m. CT
Title: Genomic Distinctions Between Colon and Rectal Cancer in Young Patients
Abstract Number: 3574
Poster Board Number: 271
Poster Display Location: Hall A
Session: Gastrointestinal (Colorectal) Cancer
Presenter: Joshua E. Meyer, M.D., assistant professor; residency/fellowship training director, department of radiation oncology, Fox Chase Cancer Center
Collaborator(s): Fox Chase Cancer Center

Date and Time: Saturday, June 4, 2016 from 8:00 - 11:30 a.m. CT
Title: MDM2 Amplification (Amp) to Mediate Cabozantinib Resistance in Patients (Pts) with Advanced RET-Rearranged Lung Cancers
Abstract Number: 9068
Poster Board Number: 391
Poster Display Location: Hall A
Session: Lung Cancer - Non-Small cell Metastatic
Presenter: Romel Somwar, Ph.D., senior research scientist, pathology, Memorial Sloan Kettering Cancer Center
Collaborator(s): Memorial Sloan Kettering Cancer Center

Date and Time: Saturday, June 4, 2016 from 8:00 - 11:30 a.m. CT
Title: Lung-MAP (S1400) Lung Cancer Master Protocol: Accrual, Demographics, and Molecular Markers
Abstract Number: 9088
Poster Board Number: 411
Poster Display Location: Hall A
Session: Lung Cancer - Non-Small Cell Metastatic
Presenter: Vassiliki Papadimitrakopoulou, M.D., professor, department of thoracic/head and neck medical oncology, medical oncology, The University of Texas MD Anderson Cancer Center
Collaborator(s): The University of Texas MD Anderson Cancer Center

Date and Time: Saturday, June 4, 2016 from 8:00 - 11:30 a.m. CT
Title: Emerging genomic landscape and therapeutic targets in young patients with colorectal cancer (CRC).
Abstract Number: 3589
Poster Board Number: 286
Poster Display Location: Hall A
Session: Gastrointestinal (Colorectal) Cancer
Presenter: Christopher Hanyoung Lieu, M.D., director, Colorectal Medical Oncology Program, deputy director, Cancer Clinical Trials Office, University of Colorado
Collaborator(s): University of Colorado

Date and Time: Saturday, June 4, 2016 from 8:00 - 11:30 a.m. CT
Title: Significant Systematic and CNS Activity of the RET Inhibitor Vandetanib Combined with mTOR inhibitor Everolimus in Patients with Advanced NSCLC with RET fusion
Abstract Number: 9069
Poster Board Number: 392
Poster Display Location: Hall A
Session: Lung Cancer - Non-Small Cell Metastatic
Presenter: Tina Cascone, M.D., Ph.D., hematology/oncology fellow, The University of Texas MD Anderson Cancer Center
Collaborator(s): The University of Texas MD Anderson Cancer Center

Date and Time: Saturday, June 4, 2016 from 1:00 - 4:30 p.m. CT
Title: TMPRSS-ERG Fusion in Men with Prostate cancer(PCa) and Non-prostate Malignancies: Defining a role for Comprehensive Genomic Profiling (CGP) to guide Clinical Care
Abstract Number: 5037
Poster Board Number: 294
Poster Display Location: Hall A
Session: Genitourinary (Prostate) Cancer
Presenter: Primo Lara, M.D., associate director for translational research, University of California, Davis
Collaborator(s): University of California, Davis

Date and Time: Saturday, June 4, 2016 from 1:00 - 4:30 p.m. CT
Title: Analysis of Tumor Mutational Burden (TMB) in > 51,000 Clinical Cancer Patients to identify Novel Non-Coding PMS2 Promoter Mutations Associated with increased TMB
Abstract Number: 9572
Poster Board Number: 177
Poster Display Location: Hall A
Session: Melanoma/Skin Cancers
Presenter: Zachary Rockow Chalmers, senior research associate, Foundation Medicine

Date and Time: Saturday, June 4, 2016 from 1:00 - 4:30 p.m. CT
Title: Comprehensive Genomic Profiling of Neuroendocrine Carcinoma of the Prostate
Abstract Number: 5027
Poster Board Number: 284
Poster Display Location: Hall A
Session: Genitourinary (Prostate) cancer
Presenter: Philip J. Stephens, Ph.D., chief scientific officer, Foundation Medicine

Date and Time: Saturday, June 4, 2016 from 1:00 - 4:30 p.m. CT
Title: Deep Sequencing of Metastatic Cutaneous Basal Cell and Squamous Cell Carcinomas to Reveal Distinctive Genomic Profiles and New Routes to Targeted Therapies
Abstract Number: 9522
Poster Board Number: 127
Poster Display Location: Hall A
Session: Melanoma/Skin Cancers
Presenter: Jeffrey S. Ross, M.D., medical director, Foundation Medicine
Collaborator(s): Albany College of Medicine

Date and Time: Saturday, June 4, 2016 from 8:00 - 11:30 a.m. CT
Title: The Genomics of Young Lung Cancer
Abstract Number: 9083
Poster Board Number: 406
Poster Display Location: Hall A
Session: Lung Cancer - Non-Small Cell Metastatic
Presenter: Barbara J. Gitlitz, M.D., associate professor of clinical medicine, University of Southern California Keck School of Medicine
Collaborator(s): University of Southern California Keck School of Medicine

Date and Time: Sunday, June 5, 2016 from 8:00 - 11:30 a.m. CT
Title: Biomarkers of Immune Checkpoint Inhibitor Response in Metastatic Breast Cancer: PD-L1 Protein Expression, CD274 Gene Amplification, and Total Mutational Burden
Abstract Number: 3057
Poster Board Number: 379
Poster Display Location: Hall A
Session: Developmental Therapeutics and Translational Research
Presenter: Jeffrey S. Ross, M.D., medical director, Foundation Medicine
Collaborator(s): Albany College of Medicine

Date and Time: Monday, June 6, 2016 from 8:00 - 11:30 a.m. CT
Title: Distinct Age-Associated Genomic Profiles Identified in Acute Myeloid Leukemia (AML) Using FoundationOne Heme
Abstract Number: 7041
Poster Board Number: 33
Poster Display Location: Hall A
Session: Hematologic Malignancies - Leukemia, Myelodysplastic Syndromes, and Allotransplant
Presenter: Katherine Tarlock, M.D., acting instructor, hematology-oncology, Seattle Children's Hospital
Collaborator(s): Fred Hutchinson Cancer Research Center

Date and Time: Monday, June 6, 2016 from 1:00 - 4:30 p.m. CT
Title: Comparison of Upper Tract Urothelial Carcinoma and Urothelial Carcinoma of the Bladder to Reveal Key Differences in Mutational Profile and Load
Abstract Number: 4522
Poster Board Number: 145
Poster Display Location: Hall A
Session: Genitourinary (Nonprostate) Cancer
Presenter: Sumanta K. Pal, M.D., assistant clinical professor, department of medical oncology & therapeutics research, City of Hope
Collaborator(s): City of Hope

Date and Time: Monday, June 6, 2016 from 1:00 - 4:30 p.m. CT
Title: Assessment of Tumor Mutation Burden from > 60,000 Clinical Cancer Patients Using Comprehensive Genomic Profiling
Abstract Number: 11558
Poster Board Number: 255
Poster Display Location: Hall A
Session: Tumor Biology
Presenter: Garrett Michael Frampton, Ph.D., associate director, bioinformatics, Foundation Medicine

Date and Time: Monday, June 6, 2016 from 1:00 - 4:30 p.m. CT
Title: Immunotherapy (IO) Versus Targeted Therapy Triage in Advanced Endometrial Adenocarcinoma (aEA) by Coordinate Assessment Tumor Mutation Burden (TMB), Microsatellite Instability (MSI) Status, and Targetable Genomic Alterations (GA)
Abstract Number: 5591
Poster Board Number: 414
Poster Display Location: Hall A
Session: Gynecologic Cancer
Presenter: Alessandro Santin, M.D., professor of obstetrics, gynecology and reproductive sciences; clinical research program leader, gynecologic oncology program, Yale School of Medicine
Collaborator(s): Yale School of Medicine

Date and Time: Monday, June 6, 2016 from 1:00 - 4:30 p.m. CT
Title: Comprehensive Genomic Profiling to Identify Clinically Relevant Genomic Alterations in Patients with Advanced Penile Cancers
Abstract Number: 4573
Poster Board Number: 195
Poster Display Location: Hall A
Session: Genitourinary (Nonprostate) Cancer
Presenter: Andre Poisl Fay, M.D.
Collaborator(s): Pontifícia Universidade Católica do Rio Grande do Sul School of Medicine

Date and Time: Monday, June 6, 2016 from 1:00 - 4:30 p.m. CT
Title: Decision Impact Analysis of Comprehensive Genomic Profiling (CGP) in Advanced Breast Cancer: A Prospective Study
Abstract Number: 11578
Poster Board Number: 275
Poster Display Location: Hall A
Session: Tumor Biology
Presenter: Raquel E. Reinbolt, M.D., assistant professor, internal medicine, college of medicine, The Ohio State University
Collaborator(s): The Ohio State University Medical Center James Comprehensive Cancer Center

Date and Time: Monday, June 6, 2016 from 1:00 - 4:30 p.m. CT
Title: Investigating the Utility of Comprehensive Genomic Profiling for Patients with Newly Diagnosed Breast Cancer
Abstract Number: TPS11617
Poster Board Number: 312b
Poster Display Location: Hall A
Session: Tumor Biology
Presenter: Casey B. Williams, Pharm.D., BCOP, director, molecular and experimental medicine, Avera Health
Collaborator(s): Avera Cancer Institute

About Foundation Medicine

Foundation Medicine (NASDAQ:FMI) is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient's unique cancer. The company offers a full suite of comprehensive genomic profiling assays to identify the molecular alterations in a patient's cancer and match them with relevant targeted therapies, immunotherapies and clinical trials. Foundation Medicine's molecular information platform aims to improve day-to-day care for patients by serving the needs of clinicians, academic researchers and drug developers to help advance the science of molecular medicine in cancer. For more information, please visit http://www.FoundationMedicine.com or follow Foundation Medicine on Twitter (@FoundationATCG).

Foundation Medicine® and FoundationOne® are registered trademarks, and FoundationACT™ is a trademark of Foundation Medicine, Inc.

Cautionary Note Regarding Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the ability of comprehensive genomic profiling, including FoundationOne, FoundationOne Heme and FoundationACT to identify genomic alterations, identify relevant therapies and improve patient outcomes; and the clinical relevance of comprehensive genomic profiling in cancer treatment and the development of targeted therapies. All such forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include the risk that the results presented are found to lack scientific, medical or clinical utility or that subsequent research renders the results presented less useful or not useful in clinical practice; Foundation Medicine's services and molecular information platform will not be able to identify genomic alterations in the same manner as prior clinical data; and the risks described under the caption "Risk Factors" in Foundation Medicine's Annual Report on Form 10-K for the year ended December 31, 2015, which is on file with the Securities and Exchange Commission, as well as other risks detailed in subsequent filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Foundation Medicine undertakes no duty to update this information unless required by law.

Media Contact:
Pure Communications, Inc.
Dan Budwick, 973-271-6085
dan@purecommunicationsinc.com
or
Investor Contact:
Foundation Medicine
Kimberly Brown, 617-418-2215
ir@foundationmedicine.com

Source: Foundation Medicine, Inc.

News Provided by Acquire Media